Dianthus Therapeutics, Inc. /DE/

Dianthus Therapeutics, Inc. /DE/

DNTH· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +89.0% in FY2025

Marino Garcia is the CEO of Dianthus Therapeutics, Inc. /DE/ and was paid $10.6M in FY2025 (Dec), up 20%.

Pay$100 in the stock at the end of FY22 → $652
CEO pay is from each Dianthus Therapeutics, Inc. /DE/ proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Marino GarciaFY2025
  2. 2Simrat Randhawa, M.D.FY2025
  3. 3Ryan SavitzFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Dianthus Therapeutics, Inc. /DE/ paid its 3 named executives $20.9M in total in FY2025 (Dec). CEO Marino Garcia was paid $10.6M of that.

Name
Marino GarciaPresident and Chief Executive Officer
Simrat Randhawa, M.D.Executive Vice President, Head of Research and Development
Ryan SavitzExecutive Vice President, Chief Financial Officer, Chief Business Officer and Treasurer

of each named executive, from the Summary Compensation Table of each proxy.

Peers19

See all

The FY2025 (Dec) proxy of Dianthus Therapeutics, Inc. /DE/ names 19 peer companies for pay. Among Dianthus Therapeutics, Inc. /DE/ and these peers, CEO pay was the highest of 7 and total shareholder return was the highest of 7.

1st highest of 7in Dianthus Therapeutics, Inc. /DE/ and its pay peers, FY2025 (Dec) by CEO pay:

$6.1M$10.6M

1st highest of 7in Dianthus Therapeutics, Inc. /DE/ and its pay peers, FY2025 (Dec) by total shareholder return:

$17$652

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Activity

  1. Pay
    Dianthus Therapeutics, Inc. /DE/ Division head pay rose 29% to $5.2M. The stock rose 89% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Dianthus Therapeutics, Inc. /DE/ CFO pay rose 27% to $5.1M. The stock rose 89% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Dianthus Therapeutics, Inc. /DE/ CEO pay rose 20% to $10.6M. The stock rose 89% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Dianthus Therapeutics, Inc. /DE/ Division head pay rose 1,093% to $4.0M. The stock rose 110% in FY2024 (Dec).
    DEF 14A
  5. Pay
    Dianthus Therapeutics, Inc. /DE/ CFO pay rose 1,114% to $4.0M. The stock rose 110% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Dianthus Therapeutics, Inc. /DE/ CEO pay rose 1,683% to $8.8M. The stock rose 110% in FY2024 (Dec).
    DEF 14A
  7. Pay
    Dianthus Therapeutics, Inc. /DE/ CFO pay rose 48% to $1.7M. The stock rose 65% in FY2023 (Dec).
    DEF 14A
  8. Pay
    Dianthus Therapeutics, Inc. /DE/ President pay fell 60% to $667.6K. The stock rose 65% in FY2023 (Dec).
    DEF 14A
  9. Pay
    Dianthus Therapeutics, Inc. /DE/ Former Chief Scientific Officer pay rose 15% to $1.1M. The stock rose 65% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 9, 2026FY2025
Annual report10-KMar 9, 2026FY2025
Proxy statementDEF 14AApr 10, 2025FY2024
Annual report10-KMar 11, 2025FY2024
Proxy statementDEF 14AApr 11, 2024FY2023
Annual report10-KMar 21, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data